0838 GMT - Bayer's prospects are improving, Berenberg analyst Sebastian Bray says in a note, citing a promising late-stage stroke prevention trial. Although the German pharmaceutical and agricultural conglomerate's late-stage trial for secondary stroke prevention is considered a long shot, there is a possibility of unexpected upside by the year end if the treatment proves significantly better than the placebo, the analyst says. "We believe there is an outside chance of a positive outcome for Bayer that may move the market's view of annual peak sales for the drug from very little to 1 billion euros or more," he says. In addition, if a Russia-Ukraine peace agreement doesn't cause a major drop in soft commodity prices, Bayer's earnings are unlikely to significantly decrease further, the analyst adds. Shares are up 1.7% at 23.65 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 10, 2025 04:38 ET (08:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。